NEW YORK, N.Y. – Pfizer Inc. on Monday released detailed analyses of myocarditis cases linked to its COVID-19 vaccine, ...
Pfizer and manufacturer Tris Pharma have agreed to hand over $41.5 million to lay to rest a 2023 lawsuit accusing the ...
Valneva's Phase 2 data show strong, lasting immunity for its Pfizer-partnered Lyme vaccine as the company consolidates operations in France.
Pfizer (NYSE: PFE) has a market cap of $135 billion. They are both pharmaceutical industry giants with long and successful ...
Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded ...
Free Malaysia Today on MSN
Pfizer, Tris Pharma settle for $41.5 million in Texas ADHD drug case
Texas's top prosecutor on Wednesday announced the state had reached a $41.5 million settlement with US drugmakers Pfizer and ...
Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported.
Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback